Article

Chondroitin Improves Hand Function in Patients With Osteoarthritis

Chondroitin sulfate significantly decreases pain and improves hand function in patients with hand osteoarthritis (OA), according to new research reported by the American College of Rheumatology (ACR). The agent also improves grip strength and relieves morning stiffness.

 

Chondroitin sulfate significantly decreases pain and improves hand function in patients with hand osteoarthritis (OA), according to new research reported by the American College of Rheumatology (ACR). The agent also improves grip strength and relieves morning stiffness.

The Finger osteoArthritis Chondroitin Treatment Study, a single-center, placebo-controlled trial, included 162 patients with radiographic hand OA. They received 800 mg of chondroitin sulfate or placebo once daily for 6 months.

Patients in the chondroitin sulfate group showed a significant decrease in global hand pain compared with the placebo group, reflecting an 8.7 decrease on the Visual Analogue Scale. They also had significantly improved hand function, with a decrease of more than 2 points on the Functional Index for Hand Osteoarthritis, and a reduction in morning stiffness.

The results were reported in Arthritis & Rheumatism, an ACR journal. For more information about hand OA and other rheumatologic conditions, visit the ACR Web site at http://www.rheumatology.org. Or, contact the organization at American College of Rheumatology, 2200 Lake Boulevard NE, Atlanta, GA 30319; telephone: (404) 633-3777; fax: (404) 633-1870.


Problems with/comments about this article? Please send feedback.

Related Videos
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
© 2024 MJH Life Sciences

All rights reserved.